Regulatory approval

Published by the Health Canada. Approved

Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression >= 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.

This is written in the approval document as:

YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC), with tumour cell PD-L1 expression >= 1% as determined by a validated test, and no prior systemic therapy for metastatic ESCC.

Citation

Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals